Neuberger Berman Group LLC Exelixis, Inc. Transaction History

Neuberger Berman Group LLC

$123 Billion
Q3 2024

A detailed history of Neuberger Berman Group LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 20,294 shares of EXEL stock, worth $679,443. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,294

Previous 11,624 74.59%

Holding current value

$679,443

Previous $261,000 101.53%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $190,393 - $239,292	8,670 Added 74.59%	20,294 $526,000
Q2 2024 Nov 14, 2024	SELL	$20.34 - $23.73 $148,359 - $173,086	-7,294 Reduced 38.56%	11,624 $261,000
Q2 2024 Aug 13, 2024	SELL	$20.34 - $23.73 $148,359 - $173,086	-7,294 Reduced 38.56%	11,624 $261,000
Q1 2024 Nov 14, 2024	SELL	$20.17 - $23.93 $4,618 - $5,479	-229 Reduced 1.2%	18,918 $448,000
Q1 2024 May 13, 2024	BUY	$20.17 - $23.93 $381,576 - $452,707	18,918 New	18,918 $448,000
Q4 2023 Nov 14, 2024	BUY	$19.25 - $24.13 $144,817 - $181,529	7,523 Added 64.72%	19,147 $459,000
Q4 2023 Feb 09, 2024	BUY	$19.25 - $24.13 $3,368 - $4,222	175 Added 0.92%	19,147 $459,000
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $158,146 - $188,878	8,306 Added 77.87%	18,972 $414,000
Q2 2023 Aug 11, 2023	BUY	$18.17 - $20.48 $4,415 - $4,976	243 Added 2.33%	10,666 $203,000
Q1 2023 May 12, 2023	BUY	$16.3 - $19.41 $169,894 - $202,310	10,423 New	10,423 $202,000
Q3 2022 Nov 15, 2022	SELL	$15.68 - $22.27 $55,522 - $78,858	-3,541 Reduced 24.26%	11,057 $173,000
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $48,116 - $63,898	-2,759 Reduced 15.9%	14,598 $304,000
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $295,589 - $393,483	17,357 New	17,357 $391,000
Q3 2019 Nov 13, 2019	SELL	$17.68 - $22.65 $10.2 Million - $13.1 Million	-578,175 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$18.93 - $24.75 $473 - $618	25 Added 0.0%	578,175 $12.4 Million
Q1 2019 May 13, 2019	SELL	$19.6 - $24.76 $3.78 Million - $4.78 Million	-192,938 Reduced 25.02%	578,150 $13.8 Million
Q4 2018 Feb 12, 2019	SELL	$13.65 - $21.8 $2.99 Million - $4.77 Million	-218,997 Reduced 22.12%	771,088 $15.2 Million
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $304,037 - $429,139	19,158 Added 1.97%	990,085 $17.5 Million
Q2 2018 Aug 13, 2018	BUY	$18.56 - $22.45 $4.78 Million - $5.78 Million	257,568 Added 36.11%	970,927 $20.9 Million
Q1 2018 May 08, 2018	BUY	$22.15 - $31.89 $14.6 Million - $21 Million	659,201 Added 1217.18%	713,359 $15.8 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $857,233 - $1.09 Million	-35,379 Reduced 39.51%	54,158 $1.68 Million
Q3 2017 Nov 15, 2017	BUY	$23.35 - $29.24 $2.09 Million - $2.62 Million	89,537	89,537 $2.17 Million

Others Institutions Holding EXEL

# of Institutions

541

Shares Held

245M

Call Options Held

2.84M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.

Account

Neuberger Berman Group LLC Exelixis, Inc. Transaction History